The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease
Background: Chronic disease appears connected to obesity. However, evidence suggests that chronic metabolic diseases are more specifically related to adipose dysfunction rather than to body weight itself. Scope of review: Further study of the first generation "insulin sensitizer" pioglitaz...
Saved in:
Main Authors: | Jerry R. Colca (Author), Philipp E. Scherer (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Challenges in drug discovery for thiazolidinedione substitute
by: Jian-ping Ye
Published: (2011) -
Design, synthesis of new 2,4-thiazolidinediones: In-silico, in-vivo anti-diabetic and anti-inflammatory evaluation
by: Shankar Gharge, et al.
Published: (2024) -
Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones
by: Andrea Benova, et al.
Published: (2022) -
Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities
by: Paolo Gisondi, et al.
Published: (2020) -
Polylactide Nanocapsules Attenuate Adverse Cardiac Cellular Effects of Lyso-7, a Pan-PPAR Agonist/Anti-Inflammatory New Thiazolidinedione
by: Giani M. Garcia, et al.
Published: (2021)